Eli Lilly Announces $30M, Five-Year Commitment To Fight NCDs In Developing Countries
U.S.-based pharmaceutical firm Eli Lilly and Company on Tuesday announced it will spend $30 million over five years to fight the rising burden of non-communicable diseases (NCDs) in developing nations, the Indianapolis Star reports (Swiatek, 9/13). According to a Lilly press release, the company is launching the Lilly NCD Partnership “to identify new models of patient care that increase treatment access and improve outcomes for underserved people” (9/13).
“The company said it is forming partnerships with hospitals and health groups,” and programs being developed with these partners “will start in early 2012,” the Associated Press/Forbes writes, adding, “The first phase will focus on diabetes care in communities in India, Brazil, Mexico and South Africa” (9/13). “The company also is sponsoring a conference in Washington, D.C., on Wednesday to discuss the treatment of non-communicable diseases such as diabetes,” the Indianapolis Star notes (9/13).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.